stockrow
Friday 6 November 2026
Export IMVT’s income statement to Excel — free account
Immunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
30.53
2.14
+7.54%
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Operating cash flow
Immunovant, Inc.'s operating cash flow for fiscal 2026 was −$407.3M, compared with −$375.9M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$414.3M. Over the past ten years it has ranged from −$407.3M (fiscal 2026) to −$28.5M (fiscal 2019) — the current reading is the lowest in ten years. Operating cash flow has fallen for 7 consecutive fiscal years. Immunovant, Inc. ranks 587th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | −$407.3M | — |
| FY2025 | −$375.9M | — |
| FY2024 | −$214.2M | — |
| FY2023 | −$188.2M | — |
| FY2022 | −$106.1M | — |
| FY2021 | −$83.3M | — |
| FY2020 | −$53.4M | — |
| FY2019 | −$28.5M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$124.4M | — |
| Mar 2026 | −$95.1M | — |
| Dec 2025 | −$92.3M | — |
| Sep 2025 | −$102.5M | — |
| 27 more quarters | Free account |
Against its own ten years
Low −$407.3M
High −$28.5M
Ten-year median
−$147.2M
Current reading's percentile
13
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $91.0M |
| PTCT PTC Therapeutics, Inc. compare | $10.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.2M |
| MANE Veradermics Incorporated compare | −$122.9M |
| KOD Kodiak Sciences Inc. compare | −$158.5M |
| CGON CG Oncology, Inc. compare | −$178.5M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$271.3M |
| IMVT Immunovant, Inc. | −$414.3M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$496.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item